"instanceType","uuid:ID","id","description","label","name","rationale"
"StudyDesign","1e937cc3-9946-4410-8654-5e64f6f9558b","StudyDesign_1","The main design for the study","","Study Design 1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated."
